Jasper Therapeutics, Inc. 8-K Filing

Ticker: JSPRW · Form: 8-K · Filed: Dec 2, 2025 · CIK: 1788028

Jasper Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyJasper Therapeutics, Inc. (JSPRW)
Form Type8-K
Filed DateDec 2, 2025
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001, $115.00
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Jasper Therapeutics, Inc. (ticker: JSPRW) to the SEC on Dec 2, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.0001 (tered) Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar); $115.00 (ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC).

How long is this filing?

Jasper Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 607 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-12-02 07:06:37

Key Financial Figures

  • $0.0001 — tered) Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar
  • $115.00 — ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC

Filing Documents

01. Other Events

Item 8.01. Other Events. On December 2, 2025, Jasper Therapeutics, Inc. (the "Company") issued a press release reporting positive preliminary clinical data from the Company's ETESIAN Phase 1b study of subcutaneous briquilimab in adult participants with allergic asthma and the completion of its internal investigation into the anomalous lack of clinical response observed in the July 2025 BEACON data for cohort 8 (240mg Q8W) and cohort 9 (240mg /180mg Q8W) and disclosing that the Company will hold a conference call and webinar at 8:00 am Eastern Time on December 2, 2025 to present findings from its investigation into the anomalous results from the BEACON study in CSU reported in July, as well as the preliminary data from the ETESIAN study in asthma. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the presentation to be used in connection with the conference call and webinar on December 2, 2025 is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated December 2, 2025. 99.2 Presentation – Jasper Therapeutics: ETESIAN Data + Beacon Investigation Update, December 2025. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 2, 2025 JASPER THERAPEUTICS, INC. By: /s/ Herb Cross Name: Herb Cross Title: Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.